Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 355,548,544
  • Shares Outstanding, K 1,767,140
  • Annual Sales, $ 54,318 M
  • Annual Income, $ 4,863 M
  • EBIT $ 13,822 M
  • EBITDA $ 22,520 M
  • 60-Month Beta 0.63
  • Price/Sales 6.56
  • Price/Cash Flow 12.75
  • Price/Book 58.71

Options Overview Details

View History
  • Implied Volatility 20.05% ( -0.85%)
  • Historical Volatility 22.32%
  • IV Percentile 50%
  • IV Rank 28.93%
  • IV High 30.36% on 10/29/24
  • IV Low 15.86% on 03/01/24
  • Put/Call Vol Ratio 0.55
  • Today's Volume 4,926
  • Volume Avg (30-Day) 17,316
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 376,606
  • Open Int (30-Day) 345,511

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 2.99
  • Number of Estimates 10
  • High Estimate 3.10
  • Low Estimate 2.95
  • Prior Year 2.79
  • Growth Rate Est. (year over year) +7.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
185.89 +8.21%
on 10/21/24
207.32 -2.97%
on 10/31/24
+7.55 (+3.90%)
since 10/07/24
3-Month
185.89 +8.21%
on 10/21/24
207.32 -2.97%
on 10/31/24
+13.65 (+7.28%)
since 08/07/24
52-Week
135.85 +48.08%
on 11/09/23
207.32 -2.97%
on 10/31/24
+59.00 (+41.50%)
since 11/07/23

Most Recent Stories

More News
TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase

Teva Pharmaceutical Industries TEVA reported third-quarter 2024 adjusted earnings of 69 cents per share, which beat the Zacks Consensus Estimate of 65 cents. Adjusted earnings rose 15% year over year.Revenues...

NVO : 106.51 (+1.09%)
JNJ : 157.16 (-0.46%)
TEVA : 17.69 (+1.49%)
ABBV : 200.11 (-0.54%)
Are Wall Street Analysts Bullish on AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

XLV : 148.83 (+0.53%)
$SPX : 5,963.21 (+0.58%)
ABBV : 200.11 (-0.54%)
Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on an operational basis, driven by higher sales of key non-COVID products like...

NVO : 106.51 (+1.09%)
LLY : 793.89 (+2.26%)
ABBV : 200.11 (-0.54%)
PFE : 27.45 (+0.33%)
Invest in the Top S&P Stocks With This New ETF

Exchange-traded funds (ETFs) are often associated with a lot of diversification. People often invest ...

MSFT : 425.37 (+1.24%)
NVDA : 148.15 (+1.74%)
AAPL : 227.12 (+1.98%)
TOPT : 25.56 (+1.27%)
ABBV : 200.11 (-0.54%)
5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs

It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly.

MO : 53.66 (-1.16%)
CVX : 157.50 (-0.14%)
VZ : 40.67 (-1.19%)
VIG : 201.67 (+0.15%)
SCHD : 28.94 (-0.34%)
ABBV : 200.11 (-0.54%)
SPYD : 45.71 (-0.37%)
O : 56.44 (-0.98%)
DGRO : 63.79 (-0.13%)
AbbVie (ABBV) Q3 2024 Earnings Call Transcript

ABBV earnings call for the period ending September 30, 2024.

ABBV : 200.11 (-0.54%)
AbbVie: Q3 Earnings Snapshot

AbbVie: Q3 Earnings Snapshot

ABBV : 200.11 (-0.54%)
3 Dividend Growth Stocks to Buy and Never Sell

These 3 dividend growth stocks have crushed the market and show no signs of slowing down.

COST : 914.20 (+1.66%)
V : 305.45 (-0.63%)
ABBV : 200.11 (-0.54%)
Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.28% this morning as strong quarterly results from Alphabet boosted sentiment, while investors also awaited a fresh batch of U.S. economic data...

PYPL : 81.62 (+0.26%)
KLAC : 682.32 (+1.89%)
GOOGL : 180.04 (+2.00%)
META : 592.63 (+3.60%)
AVGO : 183.50 (+2.20%)
RDDT : 130.60 (+7.86%)
F : 10.99 (-0.45%)
NQZ24 : 21,192.75 (+1.43%)
ABBV : 200.11 (-0.54%)
SNAP : 12.30 (+4.15%)
DASH : 170.66 (+0.60%)
GSK.LN : 1,380.000 (+0.69%)
AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Ontario

/CNW/ - AbbVie (NYSE: ABBV) announced today that Ontario has listed VRAYLAR® (cariprazine) on its provincial formulary as a General Benefit. The listing will...

ABBV : 200.11 (-0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 209.92
2nd Resistance Point 208.03
1st Resistance Point 204.62
Last Price 200.11
1st Support Level 199.32
2nd Support Level 197.43
3rd Support Level 194.02

See More

52-Week High 207.32
Last Price 200.11
Fibonacci 61.8% 180.02
Fibonacci 50% 171.59
Fibonacci 38.2% 163.15
52-Week Low 135.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar